Cargando…

John F. Fulton, Coccidioidomycosis, and Penicillin

When the late Dr. John F. Fulton contracted severe pulmonary coccidioidomycosis in January, 1942, a metastatic lesion posed the threat of further progression and fatal dissemination. The possibility that an untested and generally unavailable antibiotic, penicillin, might be of value in Fulton's...

Descripción completa

Detalles Bibliográficos
Autor principal: Tager, Morris
Formato: Texto
Lenguaje:English
Publicado: 1976
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2595496/
https://www.ncbi.nlm.nih.gov/pubmed/793204
_version_ 1782161702647758848
author Tager, Morris
author_facet Tager, Morris
author_sort Tager, Morris
collection PubMed
description When the late Dr. John F. Fulton contracted severe pulmonary coccidioidomycosis in January, 1942, a metastatic lesion posed the threat of further progression and fatal dissemination. The possibility that an untested and generally unavailable antibiotic, penicillin, might be of value in Fulton's illness led his physician, Dr. John Bumstead, to appeal directly to Fulton to obtain this antibiotic, but ostensibly for the benefit of another patient succumbing to hemolytic streptococcal infection. While of no value for Fulton, penicillin was highly successful in the treatment of his other patient and soon of a second one with staphylococcal sepsis and pneumonia. This penicillin, administered in March, 1942, was the first clinical trial of penicillin under the control of the Office of Scientific Research and Development. The unique contribution of Dr. Fulton and of his illness to this event is described.
format Text
id pubmed-2595496
institution National Center for Biotechnology Information
language English
publishDate 1976
record_format MEDLINE/PubMed
spelling pubmed-25954962008-12-05 John F. Fulton, Coccidioidomycosis, and Penicillin Tager, Morris Yale J Biol Med Medical History When the late Dr. John F. Fulton contracted severe pulmonary coccidioidomycosis in January, 1942, a metastatic lesion posed the threat of further progression and fatal dissemination. The possibility that an untested and generally unavailable antibiotic, penicillin, might be of value in Fulton's illness led his physician, Dr. John Bumstead, to appeal directly to Fulton to obtain this antibiotic, but ostensibly for the benefit of another patient succumbing to hemolytic streptococcal infection. While of no value for Fulton, penicillin was highly successful in the treatment of his other patient and soon of a second one with staphylococcal sepsis and pneumonia. This penicillin, administered in March, 1942, was the first clinical trial of penicillin under the control of the Office of Scientific Research and Development. The unique contribution of Dr. Fulton and of his illness to this event is described. 1976-09 /pmc/articles/PMC2595496/ /pubmed/793204 Text en
spellingShingle Medical History
Tager, Morris
John F. Fulton, Coccidioidomycosis, and Penicillin
title John F. Fulton, Coccidioidomycosis, and Penicillin
title_full John F. Fulton, Coccidioidomycosis, and Penicillin
title_fullStr John F. Fulton, Coccidioidomycosis, and Penicillin
title_full_unstemmed John F. Fulton, Coccidioidomycosis, and Penicillin
title_short John F. Fulton, Coccidioidomycosis, and Penicillin
title_sort john f. fulton, coccidioidomycosis, and penicillin
topic Medical History
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2595496/
https://www.ncbi.nlm.nih.gov/pubmed/793204
work_keys_str_mv AT tagermorris johnffultoncoccidioidomycosisandpenicillin